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Background: Epigenetic factors play a fundamental role in the etiopathogenesis of oral squamous cell carcinoma 
(OSCC). This study evaluated if salivary detection of P16INK4A/RASSF1A gene promoter methylation might be 
linked to the clinical/histological features of OSCC in a Colombian population.
Material and Methods: Methylation-specific polymerase chain reaction (MSP-PCR) was used to detect the me-
thylation frequency of P16INK4A/RASSF1A genes in DNA obtained from whole saliva collected of 40 healthy 
controls (HC) and 43 OSCC patients. Determination of the clinical performance of MSP-PCR assay was based 
on standard algorithms derived from two-way contingency table analysis. The association of methylation status of 
targeted genes with OSCC was analyzed in a multivariate binary logistic regression model.
Results: There were significantly higher proportions of promoter methylation of these target genes in OSCC pa-
tients when compared with HC. The analysis of single methylated genes showed high specificity, good positive 
and negative predictive values, but was accompanied by a low sensitivity. OSCC cases with clinical stage III/IV, 
poorly differentiated, and severe cellular atypia showed a significantly greater proportion of methylated than that of 
unmethylated targeted genes in saliva samples. Logistic regression analysis indicated an independent association 
of P16INK4A and RASSF1A promoter methylation with OSCC diagnosis.  A significant interaction effect between 
ageing and P16INK4A promoter methylation was also detected.
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Introduction
Oral squamous cell carcinoma (OSCC) is defined as a 
malignant epithelial tumor showing squamous differen-
tiation characterized by the formation of keratin pearls 
and/or intercellular bridges (1). It has been acknowled-
ged that environmental stimuli, including alcohol con-
sumption, smoking, chewing betel nuts, and ultraviolet 
radiation may modulate a chronic, complex, multistep, 
and sequential process of oral carcinogenesis (2) which 
finally results in abnormalities of cell growth regulation 
and differentiation (1,3). Notwithstanding, the key me-
diators that influence on this process have been not yet 
fully clarified.  Increasing evidence suggests that ma-
lignant transformation in the oral mucosa can arise as a 
result of mutations in the genes that act in the regulation 
of cell growth and in the processes of DNA repair (4), 
thus inducing cell proliferation, abnormal keratinization, 
epithelial dysplasia, cellular mobility, and angiogenesis 
(5). Likewise, several epigenetic mechanisms such as 
methylation, may alter gene expression leading to cellu-
lar functional alterations that causes abnormal division 
patterns or cell death (6-9).
The methylation phenomenon of the P16INK4A and 
RASSF1A tumor suppressor genes (TSGs), involved in 
the cell cycle control, may lead to the silencing of these 
genes, thus favoring the abnormal proliferation of the 
involved cells and tumorigenesis (10-12).  The methyla-
tion process includes the transfer of a methyl group to 
carbon 5 of cytosine in CpG dinucleotide-rich regions 
named CpG islands (13). The P16INK4A gene product 
is a negative regulator of the cell cycle that inhibits cy-
clin-dependent kinases 4 and 6 and causing the blockade 
of cell cycle progression from G1 to S phases (10-12). 
The RASSF1A gene, in turn, plays a fundamental role in 
the cell cycle control by constraining the accumulation 
of cyclin D1 and inducing cell cycle arrest (14).
It has been postulated that the analysis of DNA methyla-
tion in body fluids such as saliva possess great diagnos-
tic accuracy for timely detection of head and neck squa-
mous cell carcinoma (HNSCC) (7,15). Since not only 
OSCC is dissimilar from cancers of the other sites of 
the head and neck area (12,16), but also that epigenetic 
alterations can differ depending of ethnic populations or 
geographic areas (17,18), this study intended to inves-
tigate whether the salivary detection of P16INK4A and 
RASSF1A promoter methylation might be linked with 
the clinical and histological features of OSCC in a Co-
lombian population.
Conclusion: Salivary detection of P16INK4A and RASSF1A promoter methylation appears to be independently asso-
ciated with OSCC and may be linked to the tumor activity in the present population. Consequently, the targeting of 
these genes in saliva samples might constitute an important tool for diagnosis and prognosis purposes.
Key words: Gene methylation, oral squamous cell carcinoma, P16INK4A, RASSF1A, saliva.
Material and Methods
-Study design
This cross-sectional analytic study was conducted fo-
llowing the ethical guidelines of the Helsinki Declara-
tion and ethical approval was obtained from the Insti-
tutional Ethics Committees for Human Studies of the 
University of Antioquia (Concept Number 16-2016) and 
San Vicente Foundation University Hospital (Reference 
number 1482-2016).  Data are presented following the 
guidelines of the Strengthening the Reporting of Obser-
vational Studies in Epidemiology (STROBE) statement 
for case-control studies. The original cohort comprised 
89 volunteers evaluated between January 2017 and July 
2019 in the Stomatology and Maxillofacial Surgery Unit 
of the University Hospital San Vicente Foundation in 
Medellín (Colombia). Based on this cohort, and con-
sidering a distribution of cases and controls of 50%, 
power calculation using a web-based statistical sample 
size calculator (Raosoft® Inc., Seattle, WA, USA), ge-
nerated a sample size requirement of at least 68 partici-
pants to achieve a 90% confidence level, with an alpha 
value of 5% and a power >84% in identifying significant 
differences in the detection rate of methylation status. 
However, a major number of participants were recrui-
ted to improve the statistical power and precision. Fig. 
1 depicts the distribution of this initial cohort leading to 
the definite inclusion of 83 participants.  Once the volun-
teers signed the informed consent to be included in the 
study, they were interviewed using a standardized ques-
tionnaire with the purpose of collecting demographic 
and medical information such as gender, age, smoking 
habit, and alcohol consumption.
The study population included a group of 43 patients 
with untreated OSCC and a group of 40 healthy con-
trols (HC) with no evidence of oral or systemic disea-
se. The exclusion criteria defined were individuals that 
refused to give informed consent or not provide saliva/
tissue samples, patients previously irradiated in head 
and neck region, cases of metastatic lesions of unknown 
origin, history of oral potentially malignant disorders, 
and incomplete medical records.  An oral clinical exami-
nation was performed in all participants synchronously 
by two trained researchers (H.D. M-D. and E.A. A-P.) 
to discard the presence of pathological conditions of the 
oral mucosa that could affect the results. The clinical 
information that was gathered for OSCC group inclu-
ded the lesion size and location. Subsequently, these ca-
ses were subjected to clinical and tomographic staging 
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Fig. 1: Flow chart illustrating the progress of participants through the study.  Patients were excluded because: (a) they did not give 
consent or did not return the study forms; (b) saliva samples were not provided by the participants; (c) they declined to participate or 
have incomplete medical records.
according to previously defined criteria (19). At least 
two tissue specimens, ranging from 5 to 10 mm in size, 
were taken from different areas of patients with OSCC 
diagnosis by incisional biopsy achieved under regional 
anesthesia in an operating room by the same researchers 
that accomplished the data collection and clinical exa-
mination (H.D. M-D. and E.A. A-P.). Histological as-
sessment was made on 4 µm-thick haematoxylin-eosin 
stained sections. Ten high-power non-overlapping fields 
(400X) were examined for each tumor by a trained and 
calibrated researcher (L.V. G-P.) with a Zeiss Axiolab® 
light microscope (Carl Zeiss®, Oberkochen, Germany) 
equipped with an image analyzer system (Zen Pro®, 
Carl Zeiss®). Histological assessment considered the 
degree of invasion, presence/absence of perineural/lym-
phovascular invasion, histologic grade, cellular atypia, 
inflammatory infiltrate density, and average of mitotic/
apoptotic figures of the tumors.
Each participant provided a sample of 5 mL of unsti-
mulated whole saliva by spitting into 50 mL sterile cen-
trifuge tubes. The samples were centrifuged at 800 x g 
for 10-min and the pellet was removed to be dispersed 
using a vortex for 15-sec and stored at -20 °C until pro-
cessed. For DNA extraction, 200 µL of each pellet were 
processed with the QIAamp® DNA blood mini kit (Qia-
gen Sciences®, GmbH, Hilden, Germany) following the 
spin protocol for DNA purification from body fluids ac-
cording to manufacturer’s instructions. DNA was stored 
frozen at -20ºC until methylation-specific polymerase 
chain reaction (MSP-PCR) was performed.
Each genomic DNA sample was treated with sodium 
bisulfite for conversion of unmethylated cytosines resi-
dues into uracil, leaving unaffected the methylated cyto-
sines using the Epitect® Plus DNA Bisulfite Kit (Qiagen 
Sciences®) according to the manufacturer’s guidelines. 
The analysis of P16INK4A and RASSF1A promoter me-
thylation was performed according to established pro-
tocols (8,20).  For interpretation of results, the presence 
of any detectable amplification product using a methyla-
ted allele-specific primer set was considered as positive 
(Fig. 2).  Specific primers used for determining the me-
thylation status of the P16INK4A and RASSF1A TSGs 
are listed in Table 1.
-Statistical analysis
Data collected were analyzed using the SPSS 25.0® 
(IBM, Armonk, NY) statistical package.  Reproduci-
bility analysis for MSP-PCR assays was performed 
processing again the saliva samples obtained from 6 
participants randomly selected using the Epidat 4.0® 
(PAHO/WHO, Washington, DC, USA) software. The 
interval amongst repeated tests was six months. The 
concordance between the two series of data was quan-
tified using the Cohen’s kappa statistic (κ). Afterward, 
bivariate comparisons were performed Fisher exact test 
or Pearson’s chi-square (χ2) test in order to examine po-
tential between-group differences regarding demogra-
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Fig. 2: Representative image of a 2% (w/v) ethidium bromide-stained agarose gel showing results of MSP-PCR assay of the promoter 
hypermethylation events for P16INK4A and RASSF1A TSGs.  M indicates the presence of methylated and U indicates the presence 
of unmethylated P16INK4A and RASSF1A TSGs.  Lane 1, 100 bp DNA ladder.  Lanes 2 to 7 correspond to P16INK4A analysis as 
follows: lane 2, unmethylated human control DNA; lane 3, methylated human control DNA; lanes 4 to 7, DNA from patients; Lanes 
8 to 13 correspond to RASSF1A analysis as follows: lane 8, unmethylated human control DNA; lane 9, methylated human control 











Tumor suppressor genea Nucleotide sequenceb MSP-PCR product 
size (bp)c 
Primer sequences for stage 1 PCR (methylation-independent) 
P16INK4A Forward: 5′-GAGGAAGAAAGAGGAGGGGTTG-3′ 
Reverse: 5′-ACAAACCCTCTACCCACCTAAATC-3′ 
274 
RASSF1A Forward: 5′-GGAGGGAAGGAAGGGTAAGG-3′ 
Reverse: 5′-CAACTCAATAAACTCAAACTCCC-3′ 
260 
Stage 2 primer sequences—unmethylated allele-specific 
P16INK4A Forward: 5′-TTATTAGAGGGTGGGGTGGATTGT-3′ 
Reverse: 5′-CAACCCCAAACCACAACCATAA-3′ 
145 
RASSF1A Forward: 5′-GGTTTTGTGAGAGTGTGTTTAG-3′ 
Reverse: 5′-ACACTAACAAACACAAACCAAAC-3′ 
172 
Stage 2 primer sequences—methylated allele-specific 
P16INK4A Forward: 5′-GAGGGTGGGGCGGATCGC-3′ 
Reverse: 5′-GACCCCGAACCGCGACCG-3′ 
143 




Table 1: Description of the MSP-PCR primers used for analyzing methylation status of the P16INK4A and RASSF1A TSGs.
a Terms based on the HUGO Gene Nomenclature Committee (HGNC) database (https://www.genenames.org/)
b As per Ovchinnikov et al. (8)
c bp, base pairs
phic, clinicopathological, and molecular findings and to 
identify potential explanatory and/or confounding varia-
bles for association with OSCC.  Also, determination of 
the clinical performance of MSP-PCR assay in relation 
to diagnosis was performed using an online calculator 
(http://StatPages.info/ctab2x2.html).  Subsequently, uni-
variate and multivariate binary logistic regression analy-
ses were conducted to evaluate the association of genetic 
variables regarding OSCC whilst adjusting for demogra-
phic variables with P-value ≤0.20 identified in the bi-
variate analysis. Positive associations existed when the 
OR was >2 and the confidence range did not include 1.0. 
P values <0.05 were considered statistically significant.
Results
-Demographic and behavioral profile of the study po-
pulation
The results of evaluation of demographic and behavio-
ral parameters in the study population are displayed in 
Table 2. From this table is evident that although no sig-
nificant differences (P >0.05, χ2 test) between clinical 
groups regarding gender were detected, the age stratum 










Parameters Clinical groupsa P-value 
Healthy controls 
(n = 40) 
OSCC patients 
(n = 43) 
Gender Male  17 (42.5) 24 (55.8) 0.225b 
Female 23 (57.5) 19 (44.2) 
Age stratum <50 years 22 (55.0) 13 (30.2) 0.022b 
≥50 years 18 (45.0) 30 (69.8) 
Smoking habit Current/former 7 (17.5) 18 (41.9) 0.016b 
Non-consumer 33 (82.5) 25 (58.1) 
Alcohol consumption Current/former 10 (25.0) 20 (46.5) 0.042b 
Non-consumer 30 (75.0) 23 (55.5) 
P16INK4A methylation 
status 
Methylated 4 (10.0) 19 (44.2) 0.001c 
Unmethylated 36 (90.0) 24 (55.8) 
RASSF1A methylation status Methylated 2 (5.0) 10 (23.3) 0.018c 
Unmethylated 38 (95.0) 33 (76.7) 
 
Table 2: Bivariate comparisons of demographic parameters and gene promoter methylation status from the study population according to 
diagnosis category.
OSCC, oral squamous cell carcinoma
a Values are given as n (%) within diagnostic category
b Two-sided Pearson’s chi-square test (χ2)
c Two-sided Fisher exact test
≥50 years, current/former smokers, and current/former 
alcohol drinkers were significantly more frequent (all P 
<0.05, χ2 test) in OSCC group in comparison with HC. 
Consequently, these three later variables fulfil the con-
ditions to be considered confounders of the association 
among MSP-PCR findings and disease status.
-P16INK4A and RASSF1A methylation status
The intra-assay reproducibility was excellent for both 
P16INK4A and RASSF1A gene promoter methylation 
status (ĸ = 1.000). The results of estimation of methyla-
tion status of P16INK4A and RASSF1A TSGs are also 
presented in Table 2.  As can be seen, promoter methyla-
tion of the two targeted genes was significantly more 
frequent in OSCC patients when compared with HC (all 
P <0.05, Fisher exact test). Likewise, there was a sig-
nificant higher proportion (P <0.001, χ2 test, data not 
shown) of OSCC patients (23 cases, 53.5%) presenting 
at least one methylated marker in saliva in comparison 
with HC (5 cases, 12.5%). Conversely, although there 
was a greater number of OSCC patients presenting two 
target genes methylated (5 cases, 11.6%) when compa-
red with HC (1 case, 2.5%), this difference was not sta-
tistically significant (P >0.05, Fisher exact test, data not 
shown). In addition, promoter methylation was further 
assessed regarding significant demographic and beha-
vioral variables, irrespective of diagnosis group, in or-
der to determine variations that might potentially affect 
the results.  Accordingly, no statistical differences were 
observed among age stratum, smoking habit, and alco-
hol consumption subgroups regarding the frequency of 
P16INK4A and RASSF1A promoter methylation (all P 
values >0.05, Fisher exact and χ2 tests; data not shown), 
thus suggesting an optimal comparability of the data be-
tween cases and controls.
The analysis of the clinical performance of methylation 
status showed sensitivity values relatively low for detec-
ting methylation of P16INK4A (44.2%) and RASSF1A 
(23.3%) when analyzed individually in saliva samples. 
On the contrary, the test yielded high specificity for both 
P16INK4A (90.0%) and RASSF1A (95.0%) methylation. 
Moreover, this test also revealed relatively high po-
sitive predictive values (PPV) for P16INK4A (82.6%) 
and RASSF1A (83.3%) methylation and good negative 
predictive values (NPV) for P16INK4A (60.0%) and 
RASSF1A (53.5%) methylation. Notwithstanding, it 
was remarkable that the combined analysis of the two 
genes was able to provide a sensitivity of methylation 
detection of 53.5%, with a specificity of 87.5%, PPV of 
82.1%, and NPV of 63.6%.
-Comparison between promoter methylation status and 
clinicopathological characteristics of OSCC patients
Bivariate comparisons among promoter methylation 
status of each gene with the clinical and histological 
characteristics of the patients with diagnosis of OSCC 
are depicted in Table 3.  As can be observed, whereas 
no significant differences (P >0.05, Fisher exact and 
χ2 tests) were apparent in the methylation frequency of 
P16INK4A and RASSF1A genes with respect to location 
of the lesions, degree of invasion, perineural/lympho-
vascular invasion, inflammatory infiltrate density, nor 
apoptotic/mitotic counts, those OSCC cases with clini-
cal stage III/IV, poorly differentiated, and severe cellu-
lar atypia showed a significantly greater proportion (P 
<0.05) of methylated than unmethylated targeted genes 
in saliva samples.
-Results from multivariate binary logistic regression 
analysis
Table 4 illustrates the results from multivariate bi-
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































J Clin Exp Dent. 2020;12(5):e452-60.                                                                                                                                                                                    P16INK4A/RASSF1A methylation in OSCC
e458


































































































































































































































































































































































































































































































nary logistic regression models for the association of 
P16INK4A and RASSF1A methylation status with OSCC 
after adjusting for age stratum, smoking habit, and alco-
hol consumption.  The Hosmer-Lemeshow test values 
showed that the logistic models fit the data moderately 
well (P >0.05).  Equally, c-statistic values closer to 1.0 
for the two TSGs indicated a great discriminative power. 
It may be also appreciated that the OR for OSCC was 
significantly increased (P <0.05, Wald’s test) for patients 
with methylated P16INK4A and RASSF1A TSGs.  After 
adjusting for demographic/behavioral confounders iden-
tified in the bivariate analyses, the two biomarkers re-
mained independently associated with OSCC (P <0.05, 
Wald’s test).  Additionally, a significant synergistic bio-
logical interaction (adjusted OR, 9.17; 95% CI = 1.93 
to 43.59; P = 0.005, Wald test) could be noted between 
P16INK4A promoter methylation and age ≥50 years in 
patients with OSCC.
Discussion
Although several studies have been performed to assess 
the association of P16INK4A and RASSF1A promoter 
methylation regarding to HNSCC risk in saliva samples 
(7,8,15), to date, only two studies have focused specifi-
cally on their role in OSCC (17,21). Considering that it 
has been found evidence of substantial molecular diver-
sity between different HNSCCs (22), it would be possi-
ble to assume that methylation frequency of these two 
TSGs related to OSCC might differ with that of other 
locations of the head and neck region. Moreover, as di-
fferences in molecular characteristics of OSCC associa-
ted to geographic location have been found (17,18), the 
current study investigated whether if methylation status 
of P16INK4A and RASSF1A TSGs, as detected in sali-
va samples, might be linked with OSCC in a group of 
Colombian individuals.  Therefore, this study comprised 
a representative sample of patients with diverse clinical 
stages across the whole spectrum of disease evolution. 
Also, although cases and controls groups were relatively 
homogeneous regarding gender, parameters such as age, 
smoking habit, and alcohol consumption disclosed sig-
nificant between-group differences, and fulfil the preset 
conditions to be selected as confounders for the associa-
tion between MSP-PCR findings and OSCC in the final 
models.
It has been recognized that DNA methylation in TSGs 
is a common event in human neoplasms (23). In con-
sistency with the former, this study showed that the per-
centage of positive samples of promoter methylation for 
each TSG was significantly higher in individuals with 
OSCC when compared with HC. Additionally, 53.5% 
of cases showed methylation of at least one gene and 
11.6% had both P16INK4A and RASSF1A gene promo-
ters methylated.  In contrast, the simultaneous methyla-
tion of P16INK4A and RASSF1A gene promoters was 
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only observed in one of the controls. This is of impor-
tance because might corroborate the concept that DNA 
methylation plays a major role in OSCC development 
(21). Nevertheless, the results of methylation detection 
frequency for targeted TSGs have remained inconsis-
tent amongst the studies given the high variability of 
frequencies reported.  In the present study, the detec-
tion frequency of P16INK4A promoter methylation was 
44.2%, while other studies using saliva as a source of 
genomic DNA show detection rates of 47.8% (17) and 
17.2% (21) in OSCC, and of 47.0% (24), 29.0% (15), 
and 25.0% (8), in HNSCC. Alternatively, RASSF1A pro-
moter methylation was positive in 23.3% of the patients, 
closely equivalent to what was detected in Europeans 
(20.0%) (15), but lower that what reported in saliva ob-
tained from HNSCC patients in Australians (50.0%) (8). 
Although the present findings can have been influenced 
by ethnic factors and might reflect a geographic varia-
tion, other reasons for differences may be attributable to 
variations in sample processing and assay protocols, cli-
nical stage of the tumors, and environmental stressors.
The available evidence suggests that diagnostic accura-
cy of DNA methylation for HNSCCs varies according 
the sample type and number of markers tested (7,25). 
According to the present data, the analysis of single me-
thylated genes showed high specificity, high PPV, and 
good NPV, but was accompanied by a low sensitivity. 
Even so, the combined analysis of the two genes led to 
improve the sensitivity to 53.5% maintaining a specifi-
city of 87.5%, which concurs with the theory that DNA 
methylation detected in saliva samples had an overall 
sensitivity and specificity for HNSCC diagnosis of 47% 
and 89%, respectively (25). At the same time, and sin-
ce the combined PPV and NPV were 82.1% and 63.6% 
respectively, it would be feasible to state that combined 
salivary analysis of P16INK4A and RASSF1A gene me-
thylation was reasonably discriminatory for OSCC de-
tection in this study population.
Alongside the P16INK4A and RASSF1A promoter me-
thylation detection, several investigations have intended 
to determine an association with clinicopathologic fea-
tures. However, the results have been inconsistent, sin-
ce while some studies have not found clear evidence of 
significant associations with clinicopathologic features 
(2,6,10), others have demonstrated that methylation of 
these TSGs is significantly associated with lymph node 
metastasis (15,17), clinical stage (6,8,26), and histologic 
grade (8,15,26). In the present study, patients with stage 
III/IV tumors showed a significantly greater proportion 
of methylated than that of unmethylated targeted genes 
in saliva samples, thus suggesting that although the im-
balance of DNA methylation may be an early event in 
the carcinogenic pathway of OSCC (12), its detection 
may increase with the advancement of the tumor stage 
(8). Alternatively, those lesions exhibiting severe cellu-
lar atypia and poor histologic differentiation showed a 
significantly greater percentage of methylated than that 
of unmethylated genes in saliva samples.  Taking into 
account not only that atypia is associated with loss of 
tight junction adhesion (27), but also that aggressive tu-
mors may undergo increased rate of mechanical disso-
ciation or shedding into salivary secretions (7), it would 
be possible to hypothesize that P16INK4A/RASSF1A 
methylation may be associated with high cell prolifera-
tion yielding a high concentration of the methylated sig-
nal in exfoliated cells.  In concordance with the former, 
it has been previously stated that salivary detection of 
DNA tumor-suppressor methylation genes might mirror 
actual tumor activities and that could be used as a mar-
ker for disease progression (28).
Some researchers have established that DNA methyla-
tion may be affected by demographic variations such 
as gender, ageing, and smoking/alcohol consumption 
(12,18). Though the present findings revealed an inde-
pendent association of P16INK4A and RASSF1A gene 
methylation with disease status, a synergistic biologi-
cal interactive effect between salivary P16INK4A gene 
methylation and ageing was also present in the OSCC 
group. This finding may suggest that ageing-deleterious 
effects of oral epithelial cells could be important modi-
fying factors for the effect of P16INK4A gene methyla-
tion in OSCC. In accordance with the former, synergis-
tic patterns between ageing and DNA methylation have 
been previously acknowledged (29,30). Although it is 
difficult to establish the exact role of age-related chan-
ges in oral carcinogenesis, it has been stated that almost 
one third of the CpG sites reveal ageing-associated DNA 
methylation changes and that genes that are mandatory 
for the differentiation of epithelial cells are more likely 
to become methylated with increasing age (30).
To finalize, two limitations were evident in this research. 
First, the cross-sectional nature of this study hinders the 
assessment of a causal relationship between methylation 
of specific TSGs regarding the progression or recurrence 
of OSCC. Hence, prospective longitudinal approaches 
are required to study and establish these relationships. 
Second, the small sample size in association with the 
variability of clinicopathological patterns of disease be-
tween the study participants and selected patient popu-
lation might have influenced the results. Therefore, re-
plication in further studies with larger sample sizes and 
with other ethnicities is essential to confirm the generali-
zability of present findings. Even so, taking into account 
that the rule of thumb for stability of the estimates from 
logistic regression is to have at least 10-20 events per 
predictor used in the model, and given that there were 
19 and 10 methylated cases within the OSCC category 
for P16INK4A and RASSF1A in the adjusted model res-
pectively, it would be possible to assume that the results 
are relatively stable.
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In summary, the findings of this study suggest that sa-
livary detection of P16INK4A and RASSF1A promoter 
methylation appears to be independently associated with 
OSCC and may be linked to the tumor activity in the 
present population. Consequently, the targeting of these 
genes in saliva samples might constitute an important 
tool for diagnosis and prognosis purposes.
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